Fragile X Syndrome: From molecular pathology to therapy

Neuroscience and Biobehavioral Reviews

Volumn 46, Issue P2, 2014, Pages 242-255

  Maurin, Thomas ^a   Zongaro, Samantha ^a   Bardoni, Barbara ^a  

^a INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Actin cytoskeleton dynamics; MicroRNA; Oxidative stress; RNA binding protein; Translational regulation

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALPHA TOCOPHEROL; ARMADILLO DOMAIN PROTEIN; ARMADILLO PROTEIN P0071; BINDING PROTEIN; CYTOSKELETON PROTEIN; CYTOTOXIC NECROTIZING FACTOR 1; EPIGALLOCATECHIN GALLATE; FRAGILE X MENTAL RETARDATION PROTEIN; GUANINE QUADRUPLEX; KINESIN; MELATONIN; MEVINOLIN; MICRORNA; MINOCYCLINE; P21 ACTIVATED KINASE; PROTEIN CYFIP1; PROTEIN P70; PROTEIN PP2AC; PROTEIN RANBP9; PROTEIN RANBPM; PROTEIN TYROSINE PHOSPHATASE; PUROMYCIN; RANBP9 PROTEIN; RANBPM PROTEIN; S6 KINASE; UNCLASSIFIED DRUG;

AUTISM; CYTOSKELETON; FRAGILE X SYNDROME; GENE MUTATION; HUMAN; MAP1B GENE; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PP2AC GENE; PROTEIN FUNCTION; PROTEIN RNA BINDING; PROTEIN TARGETING; REVIEW; RNA GENE; RNA SEQUENCE; RNA STABILITY; RNA STRUCTURE; RNA TRANSPORT; SIGNAL TRANSDUCTION; TRANSLATION REGULATION; TREATMENT INDICATION; BIOLOGICAL MODEL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

CYTOSKELETON; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; MODELS, GENETIC; MOLECULAR TARGETED THERAPY; OXIDATIVE STRESS;

EID: 84909581155     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.01.006     Document Type: Review

References (141)

1. Adinolfi S., Ramos A., Martin S.R., Dal Piaz F., Pucci P., Bardoni B., Mandel J.L., Pastore A. The N-terminus of the fragile X mental retardation protein contains a novel domain involved in dimerization and RNA binding. Biochemistry 2003, 42:10437-10444.
2. Anitei M., Stange C., Parshina I., Baust T., Schenck A., Raposo G., Kirchhausen T., Hoflack B. Protein complexes containing CYFIP/Sra/PIR121 coordinate Arf1 and Rac1 signalling during clathrin-AP-1-coated carrier biogenesis at the TGN. Nat. Cell Biol. 2010, 12:330-340.
3. Ascano M., Mukherjee N., Bandaru P., Miller J.B., Nusbaum J.D., Corcoran D.L., Langlois C., Munschauer M., Dewell S., Hafner M., et al. FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 2012, 492:382-386.
4. Aschrafi A., Cunningham B.A., Edelman G.M., Vanderklish P.W. The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2180-2185.
5. Ashley C.T., Wilkinson K.D., Reines D., Warren S.T. FMR1 protein: conserved RNP family domains and selmective RNA binding. Science 1993, 262:563-566.
6. Banji D., Banji O.J., Abbagoni S., Hayath M.S., Kambam S., Chiluka V.L. Amelioration of behavioral aberrations and oxidative markers by green tea extract in valproate induced autism in animals. Brain Res. 2011, 1410:141-151.
7. Bardoni B., Abekhoukh S., Zongaro S., Melko M. Intellectual disabilities, neuronal posttranscriptional RNA metabolism, and RNA-binding proteins: three actors for a complex scenario. Prog. Brain Res. 2012, 197:29-51.
8. Bardoni B., Davidovic L., Bensaid M., Khandjian E.W. The fragile X syndrome: exploring its molecular basis and seeking a treatment. Expert Rev. Mol. Med. 2006, 8:1-16.
9. Bardoni B., Mandel J.L., Fisch G.S. FMR1 gene and fragile X syndrome. Am. J. Med. Genet. 2000, 97:153-163.
10. Bardoni B., Sittler A., Shen Y., Mandel J.L. Analysis of domains affecting intracellular localization of the FMRP protein. Neurobiol. Dis. 1997, 4:329-336.
11. Bassani S., Zapata J., Gerosa L., Moretto E., Murru L., Passaro The neurobiology of X-linked intellectual disability. Neuroscientist 2013, 9:541-552.
12. Bassell G.J., Warren S.T. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 2008, 60:201-214.
13. Beaudoin J.D., Perreault J.P. Exploring mRNA 3'-UTR G-quadruplexes: evidence of roles in both alternative polyadenylation and mRNA shortening. Nucleic Acids Res. 2013, 41:5898-5911.
14. Bechara E., Davidovic L., Melko M., Bensaid M., Tremblay S., Grosgeorge J., Khandjian E.W., Lalli E., Bardoni B. Fragile X related protein 1 isoforms differentially modulate the affinity of fragile X mental retardation protein for G-quartet RNA structure. Nucleic Acids Res. 2007, 35:299-306.
15. Bechara E.G., Didiot M.C., Melko M., Davidovic L., Bensaid M., Martin P., Castets M., Pognonec P., Khandjian E.W., Moine H., et al. A Novel Function of Fragile X Mental Retardation Protein in translational activation. PLoS Biol. 2009, 7(1):e16.
16. Benoist M., Palenzuela R., Rozas C., Rojas P., Tortosa E., Morales B., Gonzalez-Billault C., Avila J., Esteban J.A. MAP1B-dependent Rac activation is required for AMPA receptor endocytosis during long-term depression. EMBO J. 2013, 32:2287-2299.
17. Bensaid M., Melko M., Bechara E.G., Davidovic L., Berretta A., Catania M.V., Gecz J., Lalli E., Bardoni B. FRAXE-associated mental retardation protein (FMR2) is an RNA-binding protein with high affinity for G-quartet RNA forming structure. Nucleic Acids Res. 2009, 37:1269-1279.
18. Bhattacharya A., Kaphzan H., Alvarez-Dieppa A.C., Murphy J.P., Pierre P., Klann E. Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 2012, 76:325-337.
19. Brendel C., Rehbein M., Kreienkamp H.J., Buck F., Richter D., Kindler S. Characterization of Staufen 1 ribonucleoprotein complexes. Biochem. J. 2004, 384:239-246.
20. Brown V., Jin P., Ceman S., Darnell J.C., O'Donnell W.T., Tenebaum S.A., Jin X., Feng Y., Wilkinson K.D., Keene J.D., et al. Microarray identification of FMRP-associated brain mRNA and altered mRNA translational profiles in fragile X syndrome. Cell 2001, 107:477-487.
21. Busquets-Garcia A., Gomis-Gonzalez M., Guegan T., Agustin-Pavon C., Pastor A., Mato S., Perez-Samartin A., Matute C., de la Torre R., Dierssen M., et al. Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat. Med. 2013, 19:603-607.
22. Castets M., Schaeffer C., Bechara E., Schenck A., Khandjian E.W., Luche S., Moine H., Rabilloud T., Mandel J.L., Bardoni B. FMRP interferes with the Rac1 pathway and controls actin cytoskeleton dynamics in murine fibroblasts. Hum. Mol. Genet. 2005, 14:835-844.
23. Castren M. Neural stem cells. Results Probl. Cell Differ. 2012, 54:33-40.
24. Caudy A.A., Myers M., Hannon G.J., Hammond S.M. Fragile X-related protein and VIG associate with the RNA interference machinery. Genes Dev. 2002, 16:2491-2496.
25. Cesana M., Cacchiarelli D., Legnini I., Santini T., Sthandier O., Chinappi M., Tramontano A., Bozzoni I. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. Cell 2011, 147:358-369.
26. Chauhan A., Audhya T., Chauhan V. Brain region-specific glutathione redox imbalance in autism. Neurochem. Res. 2012, 37:1681-1689.
27. Chauhan A., Chauhan V. Oxidative stress in autism. Pathophysiology 2006, 13:171-181.
28. Cirillo D., Agostini F., Klus P., Marchese D., Rodriguez S., Bolognesi B., Tartaglia G.G. Neurodegenerative diseases: quantitative predictions of protein-RNA interactions. RNA 2013, 19:129-140.
29. Cory G.O., Ridley A.J. Cell motility: braking WAVEs. Nature 2002, 418:732-733.
30. Costa-Mattioli M., Sossin W.S., Klann E., Sonenberg N. Translational control of long-lasting synaptic plasticity and memory. Neuron 2009, 61:10-26.
31. D'Antoni, S., Spatuzza, M., Bonaccorso, C.M., Musumeci, S., Ciranna, L., Nicoletti, F., Huber, K.M., and Catania, M.V. Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediates signaling in disorders associated with intellectual disability and autism. Special Issue "Common mechanisms in intellectual disabilities: challenges for a translational outlook". Neurobiorev., in press.
32. Darnell J.C., Fraser C.E., Mostovetsky O., Stefani G., Jones T.A., Eddy S.R., Darnell R.B. Kissing complex RNAs mediate interaction between the Fragile-X mental retardation protein KH2 domain and brain polyribosomes. Genes Dev. 2005, 19:903-918.
33. Darnell J.C., Jensen K.B., Jin P., Brown V., Warren S.T., Darnell R.B. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 2001, 107:489-499.
34. Darnell J.C., Klann E. The translation of translational control by FMRP: therapeutic targets for FXS. Nat. Neurosci. 2013, 16:1530-1536.
35. Darnell J.C., Van Driesche S.J., Zhang C., Hung K.Y., Mele A., Fraser C.E., Stone E.F., Chen C., Fak J.J., Chi S.W., et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 2011, 146:247-261.
36. Davidovic L., Jaglin X.H., Lepagnol-Bestel A.M., Tremblay S., Simonneau M., Bardoni B., Khandjian E.W. The fragile X mental retardation protein is a molecular adaptor between the neurospecific KIF3C kinesin and dendritic RNA granules. Hum. Mol. Genet. 2007, 16:3047-3058.
37. Davidovic L., Navratil V., Bonaccorso C.M., Catania M.V., Bardoni B., Dumas M.E. A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model. Genome Res. 2011, 21:2190-2202.
38. De Cian A., Delemos E., Mergny J.L., Teulade-Fichou M.P., Monchaud D. Highly efficient G-quadruplex recognition by bisquinolinium compounds. J. Am. Chem. Soc. 2007, 129:1856-1857.
39. de Diego-Otero Y., Romero-Zerbo Y., El Bekay R., Decara J., Sanchez L., Rodriguez-de-Fonseca F., Del Arco-Herrera I. Alpha-tocopherol protect against oxidative stress in the fragile X knockout mouse:an experimental therapeutic approach for the Fmr1 deficiency. Neuropsycopharmacology 2009, 34:1011-1026.
40. De Filippis B., Fabbri A., Simone D., Canese R., Ricceri L., Malchiodi-Albedi F., Laviola G., Fiorentini C. Modulation of RhoGTPases improves the behavioral phenotype and reverses astrocytic deficits in a mouse model of Rett syndrome. Neuropsychopharmacology 2012, 37:1152-1163.
41. Derivery E., Gautreau A. Generation of branched actin networks: assembly and regulation of the N-WASP and WAVE molecular machines. Bioessays 2010, 32:119-131.
42. Diana G., Valentini G., Travaglione S., Falzano L., Pieri M., Zona C., Meschini S., Fabbri A., Fiorentini C. Enhancement of learning and memory after activation of cerebral Rho GTPases. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:636-641.
43. Dictenberg J.B., Swanger S.A., Antar L.N., Singer R.H., Bassell G.J. A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome. Dev. Cell 2008, 14:926-939.
44. Didiot M.C., Subramanian M., Flatter E., Mandel J.L., Moine H. Cells lacking the fragile X mental retardation protein (FMRP) have normal RISC activity but exhibit altered stress granule assembly. Mol. Biol. Cell 2009, 20:428-437.
45. Didiot M.C., Tian Z., Schaeffer C., Subramanian M., Mandel J.L., Moine H. The G-quartet containing FMRP binding site in FMR1 mRNA is a potent exonic splicing enhancer. Nucleic Acids Res. 2008, 36:4902-4912.
46. Dolan B.M., Duron S.G., Campbell D.A., Vollrath B., Shankaranarayana Rao B.S., Ko H.Y., Lin G.G., Govindarajan A., Choi S.Y., Tonegawa S. Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:5671-5676.
47. Dolzhanskaya N., Sung Y.J., Conti J., Currie J.R., Denman R.B. The fragile X mental retardation protein interacts with U-rich RNAs in a yeast three-hybrid system. Biochem. Biophys. Res. Commun. 2003, 305:434-441.
48. Edbauer D., Neilson J.R., Foster K.A., Wang C.F., Seeburg D.P., Batterton M.N., Tada T., Dolan B.M., Sharp P.A., Sheng M. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 2010, 65:373-384.
49. El Bekay R., Romero-Zerbo Y., Decara J., Sanchez-Salido L., Del Arco-Herrera I., Rodriguez-de-Fonseca F., de Diego-Otero Y. Enhanced markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from Fragile X mental retardation 1-deficient mice, a pathological model for Fragile X syndrome. Eur. J. Neurosci. 2007, 26:3169-3180.
50. Fahling M., Mrowka R., Steege A., Kirschner K.M., Benko E., Forstera B., Persson P.B., Thiele B.J., Meier J.C., Scholz H. Translational regulation of the human achaete-scute homologue-1 by fragile X mental retardation protein. J. Biol. Chem. 2009, 284:4255-4266.
51. Fasano S., Brambilla R. Ras-ERK signaling in behavior: old questions and new perspectives. Front. Behav. Neurosci. 2011, 5:79-85.
52. Gareau C., Houssin E., Martel D., Coudert L., Mellaoui S., Huot M.E., Laprise P., Mazroui R. Characterization of fragile X mental retardation protein recruitment and dynamics in Drosophila stress granules. PLoS ONE 2013, 8:e55342.
53. Gautier J.J., Lomakina M.E., Bouslama-Oueghlani L., Derivery E., Beilinson H., Faigle W., Loew D., Louvard D., Echard A., Alexandrova A.Y., et al. Clathrin is required for Scar/Wave-mediated lamellipodium formation. J. Cell Sci. 2011, 124:3414-3427.
54. Gecz J., Shoubridge C., Corbett M. The genetic landscape of intellectual disability arising from chromosome X. Trends Genet. 2009, 25:308-316.
55. Gilman S.R., Iossifov I., Levy D., Ronemus M., Wigler M., Vitkup D. Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron 2011, 70:898-907.
56. Gkogkas C.G., Khoutorsky A., Ran I., Rampakakis E., Nevarko T., Weatherill D.B., Vasuta C., Yee S., Truitt M., Dallaire P., et al. Autism-related deficits via dysregulated eIF4E-dependent translational control. Nature 2013, 493:371-377.
57. Gothelf D., Goraly O., Avni S., Stawski M., Hartmann A.M., Basel-Vanagaite L., Apter A. Psychiatric morbidity with focus on obsessive-compulsive disorder in an Israeli cohort of adolescents with mild to moderate mental retardation. J. Neural Transm. 2008, 115:929-936.
58. Gross C., Bassell G.J. Excess protein synthesis in FXS patient lymphoblastoid cells can be rescued with a p110beta-selective inhibitor. Mol. Med. 2012, 18:336-345.
59. Gross C., Yao X., Pong D.L., Jeromin A., Bassell G.J. Fragile X mental retardation protein regulates protein expression and mRNA translation of the potassium channel Kv4.2. J. Neurosci. 2011, 31:5693-5698.
60. Guedj F., Sebrie C., Rivals I., Ledru A., Paly E., Bizot J.C., Smith D., Rubin E., Gillet B., Arbones M., et al. Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A. PLoS ONE 2009, 4:e4606.
61. Guo W., Allan A.M., Zong R., Zhang L., Johnson E.B., Schaller E.G., Murthy A.C., Goggin S.L., Eisch A.J., Oostra B.A., et al. Ablation of Fmrp in adult neural stem cells disrupts hippocampus-dependent learning. Nat. Med. 2011, 17:559-565.
62. Halder K., Hartig J.S. RNA quadruplexes. Met. Ions Life Sci. 2011, 9:125-139.
63. Halder K., Largy E., Benzler M., Teulade-Fichou M.P., Hartig J.S. Efficient suppression of gene expression by targeting 5'-UTR-based RNA quadruplexes with bisquinolinium compounds. Chembiochem 2011, 12:1663-1668.
64. Hansen T.B., Jensen T.I., Clausen B.H., Bramsen J.B., Finsen B., Damgaard C.K., Kjems J. Natural RNA circles function as efficient microRNA sponges. Nature 2013, 495:384-388.
65. Hashimoto S., Boissel S., Zarhrate M., Rio M., Munnich A., Egly J.M., Colleaux L. MED23 mutation links intellectual disability to dysregulation of immediate early gene expression. Science 2011, 333:1161-1163.
66. Hayashi M.L., Rao B.S., Seo J.S., Choi H.S., Dolan B.M., Choi S.Y., Chattarji S., Tonegawa S. Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:11489-11494.
67. Hoeffer C.A., Santini E., Ma T., Arnold E.C., Whelan A.M., Wong H., Pierre P., Pelletier J., Klann E. Multiple components of eIF4F are required for protein synthesis-dependent hippocampal long-term potentiation. J. Neurophysiol. 2013, 109:68-76.
68. Hoeft F., Carter J.C., Lightbody A.A., Cody Hazlett H., Piven J., Reiss A.L. Region-specific alterations in brain development in one- to three-year-old boys with fragile X syndrome. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:9335-9339.
69. Huang T.Y., Chu H.C., Lin Y.L., Lin C.K., Hsieh T.Y., Chang W.K., Chao Y.C., Liao C.L. Minocycline attenuates experimental colitis in mice by blocking expression of inducible nitric oxide synthase and matrix metalloproteinases. Toxicol. Appl. Pharmacol. 2009, 237:69-82.
70. Hunsaker M.R., Wenzel H.J., Willemsen R., Berman R.F. Progressive spatial processing deficits in a mouse model of the fragile X premutation. Behav. Neurosci. 2009, 123:1315-1324.
71. Ishizuka A., Siomi M.C., Siomi H. A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev. 2002, 16:2497-2508.
72. Jacobs S., Doerig L.C. Astrocytes prevent abnormal neuronal development in the fragile X mouse. J. Neurosci. 2010, 30:4508-4514.
73. James S.J., Melnyk S., Jernigan S., Cleves M.A., Halsted C.H., Wong D.H., Cutler P., Bock K., Boris M., Bradstreet J.J., et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2006, 141B:947-956.
74. Jansen J.F. Statin therapy and cognitive deficits associated with neurofibromatosis type 1. JAMA 2008, 300:2369-2370.
75. Jin P., Zarnescu D.C., Ceman S., Nakamoto M., Mowrey J., Jongens T.A., Nelson D.L., Moses K., Warren S.T. Biochemical and genetic interaction between the fragile X mental retardation protein and microRNA patway. Nat. Neurosci. 2004, 7:113-117.
76. Jung K.M., Sepers M., Henstridge C.M., Lassalle O., Neuhofer D., Martin H., Ginger M., Frick A., DiPatrizio N.V., Mackie K., et al. Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome. Nat. Commun. 2012, 3:1080.
77. Kanai Y., Dohmae N., Hirokawa N. Kinesin transports RNA: isolation and characterization of an RNA-transporting granule. Neuron 2004, 43:513-525.
78. Karreth F.A., Tay Y., Perna D., Ala U., Tan S.M., Rust A.G., DeNicola G., Webster K.A., Weiss D., Perez-Mancera P.A., et al. In vivo identification of tumor-suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 2011, 147:382-395.
79. Kawano Y., Yoshimura T., Tsuboi D., Kawabata S., Kaneko-Kawano T., Shirataki H., Takenawa T., Kaibuchi K. CRMP-2 is involved in kinesin-1-dependent transport of the Sra-1/WAVE1 complex and axon formation. Mol. Cell. Biol. 2005, 25:9920-9935.
80. Khandjian E.W., Corbin F., Woerly S., Rousseau F. The fragile X mental retardation protein is associated with ribosomes. Nat. Genet. 1996, 12:91-93.
81. Khandjian E.W., Huot M.E., Tremblay S., Davidovic L., Mazroui R., Bardoni B. Biochemical evidence for the association of fragile X mental retardation protein with brain polyribosomal ribonucleoparticles. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:13357-13362.
82. Kelfaloui M., Pavlowsky A., Powell A.D., Valnegri P., Cheong K.W., Blandin Y., Passafaro M., Jefferys J.G.R., Chelly J., Billuard P. Inhibition of RhoA pathway rescues the endocytosis defects in Oligophrenin1 mouse model of mental retardation. Hum. Mol. Genet. 2009, 14:2575-2583.
83. Khoutorsky A., Yanagiya A., Gkogkas C.G., Fabian M.R., Prager-Khoutorsky M., Cao R., Gamache K., Bouthiette F., Parsyan A., Sorge R.E., et al. Control of synaptic plasticity and memory via suppression of poly(A)-binding protein. Neuron 2013, 78:298-311.
84. Kubo T., Yamaguchi A., Iwata N., Yamashita T. The therapeutic effects of Rho-Rock inhibitors of CNS disorders. Ther. Clin. Risk Manag. 2008, 4:605-615.
85. Kwan K.Y., Lam M.M., Johnson M.B., Dube U., Shim S., Rasin M.R., Sousa A.M., Fertuzinhos S., Chen J.G., Arellano J.I., et al. Species-dependent posttranscriptional regulation of NOS1 by FMRP in the developing cerebral cortex. Cell 2012, 149:899-911.
86. Le Brigand K., Robbe-Sermesant K., Mari B., Barbry P. miRon Top: mining microRNAs targets across large scale expression studies. Bioinformatics 2010, 26:3131-3132.
87. Leigh M.J., Nguyen D.V., Mu Y., Winarni T.I., Schneider A., Chechi T., Polussa J., Doucet P., Tassone F., Rivera S.M., et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J. Dev. Behav. Pediatr. 2013, 34:147-155.
88. Lintas C., Sacco R., Persico A.M. Genome-wide expression studies in autism spectrum disorder, Rett syndrome, and Down syndrome. Neurobiol. Dis. 2012, 45:57-68.
89. Liu-Yesucevitz L., Bassell G.J., Gitler A.D., Hart A.C., Klann E., Richter J.D., Warren S.T., Wolozin B. Local RNA translation at the synapse and in disease. J. Neurosci. 2011, 31:16086-16093.
90. Loizzo S., Rimondini R., Travaglione S., Fabbri A., Guidotti M., Ferri A., Campana G., Fiorentini C. CNF1 increases brain energy level, counteracts neuroinflammatory markers and rescues cognitive deficits in a murine model of Alzheimer's disease. PLoS ONE 2013, 8:e65898.
91. Luo Y., Shan G., Guo W., Smrt R.D., Johnson E.B., Li X., Pfeiffer R.L., Szulwach K.E., Duan R., Barkho B.Z., et al. Fragile X mental retardation protein regulates proliferation and differentiation of adult neural stem/progenitor cells. PLoS Genet. 2010, 6:e1000898.
92. Mazroui R., Huot M.E., Tremblay S., Boilard N., Labelle Y., Khandjian E.W. Fragile X Mental Retardation protein determinants required for its association with polyribosomal mRNPs. Hum. Mol. Genet. 2003, 12:3087-3096.
93. Mazroui R., Huot M.E., Tremblay S., Filion C., Labelle Y., Khandjian E.W. Trapping of messenger RNA by Fragile X Mental Retardation protein into cytoplasmic granules induces translation repression. Hum. Mol. Genet. 2002, 11:3007-3017.
94. Melko M., Bardoni B. The role of G-quadruplex in RNA metabolism: involvement of FMRP and FMR2P. Biochimie 2010, 92:919-926.
95. Memczak S., Jens M., Elefsinioti A., Torti F., Krueger J., Rybak A., Maier L., Mackowiak S.D., Gregersen L.H., Munschauer M., et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013, 495:333-338.
96. Menon R.P., Gibson T.J., Pastore A. The C terminus of fragile X mental retardation protein interacts with the multi-domain Ran-binding protein in the microtubule-organising centre. J. Mol. Biol. 2004, 343:43-53.
97. Meredith R.M., Holmgren C.D., Weidum M., Burnashev N., Mansvelder H.D. Increased threshold for spike-timing-dependent plasticity is caused by unreliable calcium signaling in mice lacking fragile X gene FMR1. Neuron 2007, 54:627-638.
98. Miles M.V., Patterson B.J., Chalfonte-Evans M.L., Horn P.S., Hickey F.J., Schapiro M.B., Steele P.E., Tang P.H., Hotze S.L. Coenzyme Q10 (ubiquinol-10) supplementation improves oxidative imbalance in children with trisomy 21. Pediatr. Neurol. 2007, 37:398-403.
99. Millevoi S., Moine H., Vagner S. G-quadruplexes in RNA biology. Wiley Interdiscip. Rev. RNA 2012, 3:495-507.
100. Miyashiro K.Y., Beckel-Mitchener A., Purk T.P., Becker K.G., Barret T., Liu L., Carbonetto S., Weiler I.J., Greenough W.T., Eberwine J. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron 2003, 37:417-431.
101. Muddashetty R.S., Nalavadi V.C., Gross C., Yao X., Xing L., Laur O., Warren S.T., Bassell G.J. Reversible inhibition of PSD-95 mRNA translation by miR-125a, FMRP phosphorylation, and mGluR signaling. Mol. Cell 2011, 42:673-688.
102. Nahirney P.C., King C.R., Christie B.R. Fmr1 knockout mice exhibit altered neuron density and synaptic structure in the dentate gyrus. FASEB J. 2011, 25. 677.10, Meeting Abstract.
103. Nakamoto M., Jin P., O'Donnell W.T., Warren S.T. Physiological identification of human transcripts translationally regulated by a specific miR. Hum. Mol. Genet. 2005, 14:3813-3821.
104. Napoli I., Mercarldo V., Boyl P.P., Eleuteri B., Zalfa F., De Rubeis S., Di Marino D., Mohr E., Massimi M., Falconi M., et al. The Fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 2008, 134:1042-1054.
105. Narayanan U., Nalavadi V., Nakamoto M., Pallas D.C., Ceman S., Bassell G.J., Warren S.T. FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A. J. Neurosci. 2007, 27:14349-14357.
106. Nolze A., Schneider J., Keil R., Lederer M., Hüttelmaier S., Kessel M.M., Qualmann B., Hatzelfeld M. FMRP regulates actin filament organization via the armadillo protein p0071. RNA 2013, 19:1483-1496.
107. Osterweil E.K., Chuang S.C., Chubykin A.A., Sidorov M., Bianchi R., Wong R.K., Bear M.F. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 2013, 77:243-250.
108. Pacey L.K., Doerig L.C. Developmental expression of FMRP in the astrocyte lineage: implications for fragile X syndrome. Glia 2007, 55:1601-1609.
109. Pavlowsky A., Chelly J., Billuart P. Emerging major synaptic signaling pathways involved in intellectual disability. Mol. Psychiatry 2012, 17:682-693.
110. Pfeiffer B.E., Huber K.M. Fragile X mental retardation protein induces synapse loss through acute postsynaptic translational regulation. J. Neurosci. 2007, 27:3120-3130.
111. Piccoli C., Izzo A., Scrima R., Bonfiglio F., Manco R., Negri R., Quarato G., Cela O., Ripoli M., Prisco M., et al. Chronic pro-oxidative state and mitochondrial dysfunctions are more pronounced in fibroblasts from Down syndrome foeti with congenital heart defects. Hum. Mol. Genet. 2013, 22:1218-1232.
112. Pittman A.J., Gaynes J.A., Chien C.B. nev (cyfip2) is required for retinal lamination and axon guidance in the zebrafish retinotectal system. Dev. Biol. 2010, 344:784-794.
113. Plante I., Provost P. Hypothesis: a role for fragile X mental retardation protein in mediating and relieving miR-guided translational repression?. J. Biomed. Biotechnol. 2006, 2006:64347.
114. Plasschaert, R.N., Bartolomei, M.S., 2013. Autism: a long genetic explanation. Nature, doi:10.1038/nature12553.
115. Poliseno L., Salmena L., Zhang J., Carver B., Haveman W.J., Pandolfi P.P. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010, 465:1033-1038.
116. Romero-Zerbo Y., Decara J., El Bekay R., Dsanchez-Salido L., Arco-Herrera I.D., de Fonseca F.R., de Diego Otero Y. Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: a therapeutic research model for the fragile X syndrome. J. Pineal Res. 2008, 46:224-234.
117. Rossignol D.A., Frye R.E. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol. Psychiatry 2012, 17:389-401.
118. Salmena L., Poliseno L., Tay Y., Kats L., Pandolfi P.P. A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language?. Cell 2011, 146:353-358.
119. Santini E., Huynh T.N., MacAskill A.F., Carter A.G., Pierre P., Ruggero D., Kaphzan H., Klann E. Exaggerated translation causes synaptic and behavioural aberrations associated with autism. Nature 2013, 493:411-415.
120. Scantlebury N., Zhao X.L., Rodriguez Moncalvo V.G., Camiletti A., Zahanova S., Dineen A., Xin J.H., Campos A.R. The Drosophila gene RanBPM functions in the mushroom body to regulate larval behavior. PLoS ONE 2010, 5:e10652.
121. Schaeffer C., Bardoni B., Mandel J.L., Ehresmann B., Ehresmann C., Moine H. The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif. EMBO J. 2001, 20:4803-4813.
122. Schenck A., Bardoni B., Langmann C., Harden N., Mandel J.L., Giangrande A. CYFIP/Sra-1 controls neuronal connectivity in Drosophila and links the Rac1 GTPase pathway to the fragile X protein. Neuron 2003, 38:887-898.
123. Schenck A., Bardoni B., Moro A., Bagni C., Mandel J.L. A highly conserved protein family interacting with the fragile X mental retardation protein (FMRP) and displayng selective interaction with FMRP-related proteins FXR1P and FXR2P. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:8844-8849.
124. Schutt J., Falley K., Richter D., Kreienkamp H.J., Kindler S. Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. J. Biol. Chem. 2009, 284:25479-25487.
125. Seitz H. Redefining miR targets. Curr Biol 2009, 19:870-873.
126. Serrano F., Klann E. Reactive oxygen species and synaptic plasticity in the aging hippocampus. Ageing Res. Rev. 2004, 3:431-443.
127. Sharma A., Hoeffer C.A., Takayasu Y., Miyawaki T., McBride S.M., Klann E., Zukin R.S. Dysregulation of mTOR signaling in fragile X syndrome. J. Neurosci. 2010, 30:694-702.
128. Sierra C., Vilaseca M.A., Brandi N., Artuch R., Mira A., Nieto M., Pineda M. Oxidative stress in Rett syndrome. Brain Dev. 2001, 23(Suppl1):S236-S239.
129. Siller S.S., Broadie K. Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloprotease. Dis. Model. Mech. 2011, 4:673-685.
130. Stefani G., Fraser C.E., Darnell J.C., Darnell R.B. Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells. J. Neurosci. 2004, 24:9272-9276.
131. Subramanian M., Rage F., Tabet R., Flatter E., Mandel J.L., Moine H. G-quadruplex RNA structure as a signal for neurite mRNA targeting. EMBO Rep. 2011, 12:697-704.
132. Sumazin P., Yang X., Chiu H.S., Chung W.J., Iyer A., Llobet-Navas D., Rajbhandari P., Bansal M., Guarnieri P., Silva J., et al. An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell 2011, 147:370-381.
133. Sung Y.J., Conti J., Currie J.R., Brown W.T., Denman R.B. RNAs that interact with the fragile X syndrome RNA binding protein FMRP. Biochem. Biophys. Res. Commun. 2000, 275:973-980.
134. Valenti D., de Bari L., Manente G.A., Rossi L., Mutti L., Moro L., Vacca R.A. Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells. Biochim. Biophys. Acta 2013, 1832:2085-2096.
135. Valenti D., De Rasmo D., Signorile A., Rossi L., de Bari L., Scala I., Granese B., Papa S., Vacca R.A. Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndrome. Biochim. Biophys. Acta 2013, 1832:542-552.
136. Valiyaveettil M., Bentley A.A., Gursahaney P., Hussien R., Chakravarti R., Kureishy N., Prag S., Adams J.C. Novel role of the muskelin-RanBP9 complex as a nucleocytoplasmic mediator of cell morphology regulation. J. Cell Biol. 2008, 182:727-739.
137. Wang H., Dictenberg J.B., Ku L., Li W., Bassell G.J., Feng Y. Dynamic association of the fragile X mental retardation protein as a messenger ribonucleoprotein between microtubules and polyribosomes. MBC 2008, 19:105-114.
138. Westmark C.J., Malter J.S. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 2007, 5:e52.
139. Wilson B.M., Cox C.L. Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:2454-2459.
140. Zhang Y.Q., Bailey A.M., Matthies H.J., Renden R.B., Smith M.A., Speese S.D., Rubin G.M., Broadie K. Drosophila fragile X-related gene regulates MAP1B homolog FUTSCH to control synaptic structure and function. Cell 2001, 107:591-603.
141. Zongaro S., Hukema R., D'Antoni S., Davidovic L., Barbry P., Catania M.V., Willemsen R., Mari B., Bardoni B. The 3' UTR of FMR1 mRNA is a target of miR-101, miR-129-5p and miR-221: implications for the molecular pathology of FXTAS at the synapse. Hum. Mol. Genet. 2013, 22:1971-1982.